Blar i Bergen Open Research Archive på forfatter "Hansen, Simen Hyll"
-
Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis
Kummen, Martin; Thingholm, Louise B.; Rühlemann, Malte C.; Holm, Kristian; Hansen, Simen Hyll; Moitinho-Silva, Lucas; Liwinski, Timur; Zenouzi, Roman; Larsen, Christopher Storm; Midttun, Øivind; McCann, Adrian; Ueland, Per Magne; Høivik, Marte Lie; Vesterhus, Mette; Trøseid, Marius; Laudes, Matthias; Lieb, Wolfgang; Karlsen, Tom Hemming; Bang, Corinna; Schramm, Christoph; Franke, Andre; Hov, Johannes Espolin Roksund (Journal article; Peer reviewed, 2021)Background & Aims To influence host and disease phenotype, compositional microbiome changes, which have been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanied by functional changes. ... -
NLRP3 inflammasome deficiency attenuates metabolic disturbances involving alterations in the gut microbial profile in mice exposed to high fat diet
Sokolova, Marina; Yang, Kuan; Hansen, Simen Hyll; Louwe, Mieke C.; Kummen, Martin; Hov, Johannes Espolin Roksund; Sjaastad, Ivar; Berge, Rolf Kristian; Halvorsen, Bente; Aukrust, Pål; Yndestad, Arne; Ranheim, Trine (Journal article; Peer reviewed, 2020)Obesity-related diseases (e.g. type 2 diabetes mellitus and cardiovascular disorders) represent an increasing health problem worldwide. NLRP3 inflammasome activation may underlie obesity-induced inflammation and insulin ... -
Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial
Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Peer reviewed, 2021)Background The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast ...